ERIC TOPOL THE CREATIVE DESTRUCTION OF MEDICINE PDF

In his productive career as a physician-scientist, he has built an international reputation for his ground-breaking research and expertise. Of special interest to Dr. Topol are genomics, wireless sensors, preventive cardiology including heart attack prevention , coronary artery disease and preventive medicine. The research that Dr. Topol has done on genomic and wireless digital technologies continues to reshape the future of medicine.

Author:Goltitaxe Zutaxe
Country:Italy
Language:English (Spanish)
Genre:History
Published (Last):20 May 2016
Pages:229
PDF File Size:20.84 Mb
ePub File Size:8.47 Mb
ISBN:473-3-56082-200-1
Downloads:95024
Price:Free* [*Free Regsitration Required]
Uploader:Fenrikree



Topol pioneered the development of many medications that are routinely used in medical practice including t-PA , Plavix , Angiomax , and ReoPro. He has led worldwide clinical trials in over 40 countries involving over , patients First in series — GUSTO trials.

Topol was a tenured Professor at the University of Michigan for 6 years. At age 36, Topol was named Chairman of Cardiovascular Medicine at the Cleveland Clinic , where he is widely credited with leading its cardiovascular program to the topmost position in the US. During his training at Johns Hopkins University , he was involved from the very first patient who was administered t-PA in , a genetically engineered protein. Both thrombospondin variants and the MEF2A deletion reports were recognized as top 10 advances by the American Heart Association in and , as mentioned above.

Steven Steinhubl, [14] Ali Torkamani, [15] and Nathan Wineinger, [16] and has multiple NIH funded projects on genomics of cancer, aging, cardiovascular disease, pharmacogenomics and diabetes.

In , Topol led the team at Scripps to be the first center to perform routine genotyping of patients undergoing stenting for variants of the gene CYP2C19 , the major gene implicated in Plavix metabolism.

Also in , he initiated the Association for Genomic Medicine that is dedicated to training physicians in genomics. In he joined the Board of Sotera Wireless that has developed the first continuous non-invasive blood pressure monitoring device, which also captures all vital signs.

His report suggested that within ten years most patients would be managing their own long-term conditions with wearable devices and sensors, and that that would be much more effective than occasional appointments with a doctor. Patients would not be monitored in hospital but at home. This rise in regular monitoring would necessitate new workflows and frameworks in digital healthcare. Topol gained prominence as the first physician researcher to raise questions about the safety of rofecoxib Vioxx.

She reported that Topol served as a scientific advisor to a hedge fund which profited substantially by short selling Merck stock, which plummeted due to the concerns about Vioxx which Topol had publicized.

The Clinic described the timing as coincidental. In , Topol received the Hutchinson Medal from the University of Rochester in addition to giving the commencement speech for the School of Medicine and Dentistry.

In , Modern Healthcare ranked Topol as the most influential physician executive in the United States. New York: Basic Books, —.

FORMATION LOGICIEL COVADIS PDF

The Creative Destruction of Medicine

Topol pioneered the development of many medications that are routinely used in medical practice including t-PA , Plavix , Angiomax , and ReoPro. He has led worldwide clinical trials in over 40 countries involving over , patients First in series — GUSTO trials. Topol was a tenured Professor at the University of Michigan for 6 years. At age 36, Topol was named Chairman of Cardiovascular Medicine at the Cleveland Clinic , where he is widely credited with leading its cardiovascular program to the topmost position in the US. During his training at Johns Hopkins University , he was involved from the very first patient who was administered t-PA in , a genetically engineered protein. Both thrombospondin variants and the MEF2A deletion reports were recognized as top 10 advances by the American Heart Association in and , as mentioned above. Steven Steinhubl, [14] Ali Torkamani, [15] and Nathan Wineinger, [16] and has multiple NIH funded projects on genomics of cancer, aging, cardiovascular disease, pharmacogenomics and diabetes.

LEY 28389 PDF

The Creative Destruction of Medicine

.

AGOSTO CONDADO DE OSAGE PDF

Eric Topol, MD

.

Related Articles